Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Financial Results
March 15, 2021 07:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
●Phase 3 study of lenabasum in dermatomyositis on schedule for topline data in Q2 2021 ●Company focused on advancing in-house programs in metabolic diseases, fibrotic disorders, and cancer with...
Corbus Pharmaceuticals Announces Corporate Restructuring and Pipeline Portfolio Updates
October 08, 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Company is restructuring with the goal of extending cash runway to mid-2022Workforce to be reduced by 54%Company to focus on completing Phase 3 dermatomyositis study and advancing preclinical pipeline...
Corbus Pharmaceuticals Reports 2019 Second Quarter Financial Results and Provides Clinical and Corporate Updates
August 08, 2019 07:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Clinical development of lenabasum on target for 2020 data readouts in lead indications systemic sclerosis and cystic fibrosis; diseases affect ~270,000 people total in U.S., EU and Japan CRB-4001 on...
DEADLINE MONDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Corbus Pharmaceuticals Holdings, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
May 10, 2019 11:40 ET
|
Schall Law
LOS ANGELES, May 10, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Corbus Pharmaceuticals...
Corbus Pharmaceuticals Reports 2019 First Quarter Financial Results and Provides Clinical Updates
May 09, 2019 07:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Continued progress made in four ongoing clinical studies as lenabasum advances towards 2020 data readouts in lead indications systemic sclerosis and cystic fibrosis Second clinical candidate...
INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Corbus Pharmaceuticals Holdings, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
May 03, 2019 20:21 ET
|
Schall Law
LOS ANGELES, May 03, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Corbus Pharmaceuticals...
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Corbus Pharmaceuticals Holdings, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
April 26, 2019 09:15 ET
|
Schall Law
LOS ANGELES, April 26, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Corbus Pharmaceuticals...
Block & Leviton LLP Announces It Has Filed A Securities Class Action Against Corbus Pharmaceuticals And Encourages Shareholders To Contact The Firm
March 12, 2019 17:18 ET
|
Block & Leviton LLP
BOSTON, March 12, 2019 (GLOBE NEWSWIRE) -- Block & Leviton LLP (www.blockesq.com), a Boston based securities litigation firm representing investors nationwide, has filed a securities fraud class...
Corbus Pharmaceuticals to Present at the Oppenheimer 29th Annual Healthcare Conference
March 11, 2019 08:35 ET
|
Corbus Pharmaceuticals Holdings, Inc.
- Presentation with live audio webcast on Tuesday, March 19, 2019 at 2:10 p.m. ET- Norwood, MA, March 11, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or...
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Corbus Pharmaceuticals Holdings, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
March 05, 2019 14:59 ET
|
Schall Law
LOS ANGELES, March 05, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corbus...